Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
Conditions: Non Small Cell Lung Cancer; ALK Gene Mutation Interventions: Drug: Brigatinib 180 MG; Drug: Carboplatin; Drug: Pemetrexed Sponsor: Intergroupe Francophone de Cancerologie Thoracique Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials